About US
Contact us
Position：Home > Phexcom News >
-
With $10B deal hunt, Amgen looks even more like Big PharmaAmgen ($AMGN) has been edging toward a Big Pharma qualification for some time--not only with annual revenues that last year surpassed Eli Lilly & Co. ($LLY) and Bristol-Myers Squibb ($BMY), but wi2015/11/11
-
Allergan, shut down on Namenda hard switch, takes it up with SCOTUSEarlier this year, when a U.S. appeals court officially thwarted Allergan's ($AGN) plan to force patients over to a new, patent-protected version ofNamendabefore generics hit, it looked like doom for2015/11/11
-
UPDATED: Chicago makes second run at Allergan, J&J, Purdue and others with painkiller lawsuitOpioid makers thought they had dodged a litigation bullet6 months agowhen a federal judge dismissed a lawsuit by the City of Chicago trying to hold them accountable for an "epidemic" of painkiller, an2015/11/10
-
Sanofi's back-to-growth strategy fails to impress analystsIf Sanofi ($SNY) CEOOlivier Brandicourtwanted to win over analysts with Friday's pronouncements about the company's future, he must be disappointed now. A slew of investment firms cut their price targ2015/11/10
-
How badly does Pfizer need a tax inversion? Depends how you parse the numbersHow big is Pfizer's "tremendous disadvantage" from its U.S. tax rate? Bigger when you report your foreign earnings the way the pharma giant does. Pfizer told shareholders it had a 25.5% global tax ra2015/11/10
-
Dr. Reddy's feels FDA heat, gets warning letter for three plantsA regulatory hammer has been hanging over Dr. Reddy's Laboratories ($RDY) since theFDAwrote up one of its plants for falling short of quality standards. That hammer has now fallen hard with thedrugmak2015/11/9
-
Valeant board, Ackman back CEO Pearson as shares continue downward diveValeant's ($VRX) stock price may have hit its lowest point in more than two years, but the company's board and enthusiast investorBill Ackmanstill say CEOJ. Michael Pearsonis the one for the job. On2015/11/9
-
Boehringer Ingelheim picks family member to lead it through tough timesBoehringer Ingelheimis going back to the future, picking a member of the founding family as CEO for the first time in a quarter of a century to help it through its lean times. The drugmaker announced2015/11/9
-
Eliquis, Opdivo push up Bristol-Myers' quarterly ad spendBristol-Myers Squibb ($BMY) spent Q3 competing in a couple of hot market races--and for that, it needed more ad dollars. Thecompany's advertising and product promotion costs rose 13% to $193 million f2015/11/5
-
Allergan delivers 'decent' Q3 sales growth, with price hikes driving half of itAll eyes are on Allergan's ($AGN) friendly deal talks with Pfizer ($PFE), which is anxious to scoop up an acquisition and complete a tax inversion. But with the Irish drugmaker's execs mum on the poss2015/11/5